Being recognized by @FastCompany’s Most Innovative Companies proves that pushing boundaries and always innovating is the path towards making sure people receive the care they need to live their fullest life.
We’re encouraged to see @GeneticCouns, @GeneticsSociety, and @TheACMG release a joint statement on autism and genetics. At GeneDx, we’re proud to support continued progress in genomic insights for patients and families.
Learn more: https://t.co/3d80Gnrr6H
#Autism#Genetics
Don't miss out! Register now to learn how integrated genomic and claims data can support precision clinical trials, natural history modeling, biomarker discovery, and evidence generation at scale.
➡️ Thursday, June 4 at 1 PM EDT | 10 AM PDT
https://t.co/rB1QKj7n1H
John Wollman @KomodoHealth discusses how the company and @GeneDx are leveraging longitudinal patient data with genomic and phenotypic data to shorten rare disease diagnostic odysseys, accelerate natural hist studies, and enable better clinical decisions.
https://t.co/Lu91t2Hmbw
Another clip from this week's #HealthcareUnfiltered podcast with @GeneDx President and CEO, Katherine Stueland who describes how the focus on rare diseases using genomics will help patients world-wide. An inspiring interview streaming everywhere.
https://t.co/Jow49PI00a
What does leadership look like in healthcare today?
Our CEO Katherine Stueland shares her perspective on #HealthcareUnfiltered.
Episode out tomorrow. 🎧
Tom on #HealthcareUnfiltered, you're in for a treat as I host the President & CEO of @GeneDx Katherine Stueland who under her leadership, the company is making major strides in combatting "rare diseases' through genomics.
Wide range interview W many lessons learned. Pls tune in
Tom on #HealthcareUnfiltered, you're in for a treat as I host the President & CEO of @GeneDx Katherine Stueland who under her leadership, the company is making major strides in combatting "rare diseases' through genomics.
Wide range interview W many lessons learned. Pls tune in
We’re proud to partner with @GeneDx to launch a Sponsored Genetic Testing Program for eligible patients in the U.S. with suspected Niemann-Pick disease type C (NPC).
Read the press release: https://t.co/oVBDXKS2fj
#RareDisease#NPC#GeneticTesting
Rare disease isn’t rare. It’s one of healthcare’s biggest blind spots.
In @FastCompany Impact Council, our CMO Linda Genen, MD, MPH shares why genomics can shorten years to days and bring clarity to care.
Read more → https://t.co/WwBHY0cKDU
In this short video, Mimi C. Lee, MD, PhD, explains the mechanism of whole genome and exome testing, highlighting @GeneDx's ExomeDx test and GenomeDx tests.
Watch the full interview with Lee, and learn more about genetic testing: https://t.co/yuucpiJKzj
Katherine Stueland, CEO of @GeneDx, on using early genomics to end the diagnostic odyssey and bring answers to more families.
Apple: https://t.co/AWwOfgG8A5
Spotify: https://t.co/vjk9yrf9sZ
Acast:
https://t.co/454VcqhwBE
#Genomics#PrecisionMedicine#RareDisease#screening
Up to 50% of unexplained epilepsy cases have a genetic cause, yet many go undetected.
Dr. Isabella Herman of Boys Town National Research Hospital shares how genetic testing is transforming epilepsy care.
This #EpilepsyAwarenessMonth, we’re teaming with @GeneDx to highlight how genetic testing can uncover the root cause of seizures and help providers deliver more precise, personalized care.
👏 Thrilled to have @GeneDx join #FierceHealthPayerSummit 2025 as a Gold Partner! Dec 3–5 in Nashville — payers, providers & innovators unite to address prior authorization & health equity.
Details: https://t.co/XwKgclNqwR
#HealthPayer
Fabric Genomics and @GeneDx are enabling decentralized testing powered by centralized intelligence. Together, we harness the power of data to deliver actionable genomic insights. Visit us at #ASHG2025
https://t.co/tEnmf8hqIT
#WGS
What’s next for #GeneTherapy and #CellTherapy?
#NORD + @ASGCTherapy co-hosted a #NORDSummit panel on promising, cutting-edge science—and the challenges of access, affordability and equity. Featuring experts from @UMassChan and @GeneDx.
Patient voices + FUNDING = New treatments
At ASHG, Illumina Pilots Products for Mapped Reads, Multiomics
The company shared pilot data about its Constellation tech and released 5-Base, a product for jointly analyzing genetic and epigenetic data
@illumina@GeneDx#multiomics#DNAmethylation#ASHG
https://t.co/3uZWN9GQsz
We’ve spent years pushing the limits of what short-read sequencing can do. Now, with our emerging constellation mapped read technology, we’re breaking new barriers and enabling the industry to uncover even deeper insights from the genome.
@GeneDx recently piloted constellation to evaluate its performance in the most challenging genomic regions. Early results illustrate its ability to rapidly identify hard-to-detect variants implicated in rare disease, like DMPK, SMN1, and mosaic aneuploidy.
Joe Devaney, Director of the Laboratory Innovation Team at GeneDx, said: “We’re continually looking to advance research and clinical genomics to drive the future of precision medicine and better health outcomes for all. The level of detail we can achieve with Constellation provides promising insight into some of the world’s most complex and difficult-to-diagnose diseases.”
Constellation delivers long-range genomic insights with a simplified, on-flow-cell library prep that removes manual steps — all within the workflows our customers know and trust.
📍GeneDx presented the results of their pilot today at #ASHG25. Read more here: https://t.co/P1B86PUwfb